Catargi Bogdan, Rigalleau Vincent, Poussin Agathe, Ronci-Chaix Nathalie, Bex Veronique, Vergnot Vincent, Gin Henri, Roger Patrick, Tabarin Antoine
Department of Endocrinology, Institut de Recherche en Nutrition Humaine en Aquitaine, University Hospital of Bordeaux, 33604 Pessac, France.
J Clin Endocrinol Metab. 2003 Dec;88(12):5808-13. doi: 10.1210/jc.2003-030254.
Subclinical Cushing's syndrome (SCS) caused by adrenal incidentalomas is frequently associated with overweight and insulin resistance. Metabolic syndrome X may therefore be a clue to the presence of CS. However, the incidence of CS in this situation remains unknown. We have conducted a prospective study to evaluate the prevalence of occult CS in overweight, type-2 diabetic patients devoided of specific clinical symptoms of CS. Two hundred overweight, type-2 diabetic patients, consecutively referred for poor metabolic control (HbA(1C) > 8%), were studied as inpatients. A first screening step was performed with the 1-mg overnight dexamethasone suppression test (DST) using a revised criterion for cortisol suppression (60 nmol/liter) to maximize the sensitivity of the procedure. A second confirmatory step of biochemical investigations (midnight plasma cortisol concentration, plasma cortisol circadian rhythm, morning plasma ACTH concentration, 24-h urinary free cortisol, and 4-mg i.v. DST) was performed in patients with impaired 1-mg DST. A third step of imaging studies was performed according to the results of second-step investigations. Fifty-two patients had impaired 1-mg DST. Among these, 47 were further evaluated. Thirty were considered as false positives of the 1-mg DST, whereas 17 displayed at least one additional biological abnormality of the hypothalamic-pituitary-adrenal axis. Definitive occult CS was identified in four patients (2% of the whole series) with Cushing's disease (n = 3) and surgically proven adrenal adenoma (n = 1). Definitive diagnosis remains to be established in seven additional patients (3.5%) with mild occult CS associated with unsuppressed plasma ACTH concentrations and a unilateral adrenal tumor of 10-29 mm in size showing prevalent uptake at radiocholesterol scintigraphy. In conclusion, a relatively high prevalence of occult CS was found in our study. Further studies are needed to evaluate the impact of the cure of occult CS on obesity and diabetes mellitus in these patients. Such studies might provide a rationale for systematic screening of occult CS in this population.
肾上腺偶发瘤所致的亚临床库欣综合征(SCS)常与超重和胰岛素抵抗相关。因此,代谢综合征X可能是存在库欣综合征(CS)的线索。然而,这种情况下CS的发病率仍不清楚。我们进行了一项前瞻性研究,以评估无CS特异性临床症状的超重2型糖尿病患者中隐匿性CS的患病率。连续收治了200例因代谢控制不佳(糖化血红蛋白>8%)而转诊的超重2型糖尿病患者作为住院患者。第一步筛查采用1毫克过夜地塞米松抑制试验(DST),使用修订后的皮质醇抑制标准(60纳摩尔/升)以最大化该检查的敏感性。对1毫克DST结果异常的患者进行第二步生化检查(午夜血浆皮质醇浓度、血浆皮质醇昼夜节律、上午血浆促肾上腺皮质激素浓度、24小时尿游离皮质醇以及4毫克静脉注射DST)进行确认。根据第二步检查结果进行第三步影像学检查。52例患者1毫克DST结果异常。其中,47例进一步接受评估。30例被认为是1毫克DST的假阳性,而17例显示下丘脑 - 垂体 - 肾上腺轴至少有一项其他生物学异常。4例患者(占整个系列的2%)被确诊为隐匿性CS,其中3例为库欣病,1例为手术证实的肾上腺腺瘤。另外7例患者(3.5%)诊断尚未明确,这些患者存在轻度隐匿性CS,伴有血浆促肾上腺皮质激素浓度未被抑制,以及大小为10 - 29毫米的单侧肾上腺肿瘤,放射性胆固醇闪烁显像显示有明显摄取。总之,我们的研究发现隐匿性CS的患病率相对较高。需要进一步研究来评估隐匿性CS的治愈对这些患者肥胖和糖尿病的影响。此类研究可能为对该人群系统筛查隐匿性CS提供理论依据。